2012
London, UK, 12 June 2012 BTG plc (LSE: BTG), the specialist healthcare company, notes today’s announcement by Sanofi and its subsidiary Genzyme, relating to the submission of a supplemental...
West Conshohocken, PA, 04 June 2012 BTG International Inc., the specialist healthcare company, today announces the presentation of data on Voraxaze®(glucarpidase) at the American Society of...
London, UK, 25 May 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces that Louise Makin, CEO, will be presenting at the Jefferies Global Healthcare Conference in New York,...
London, UK, 21 May 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces its final results for the year ended 31 March 2012. Click here to download the PDF
West Conshohocken, PA, 30 April 2012 BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze® (glucarpidase) in the US. Voraxaze® is indicated for the...
London, UK, 23 April 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces the successful outcome of VANISH-1, the second and final US pivotal Phase III trial of Varisolve®...
London, UK, 04 April 2012 BTG plc (LSE: BGC), the specialist healthcare company, provides the following update for the year ended 31 March 2012 ahead of the planned publication of its Final...
London, UK, 28 March 2012 Powder for solution for infusion Launched in the UK, BTG, the specialist healthcare company today announces the launch of DigiFab® in the UK through Protherics Medicines...
London, UK, 08 March 2012 Regulatory applications to be submitted in the US and around the world beginning in H2 2012 seeking approval for use in men with CRPC who have not yet received...
London, UK, 20 February 2012 BTG plc (LSE: BGC), the specialist healthcare company today announces that it will be presenting at the Citi Global Health Care Conference in New York, US on Tuesday,...
London, UK, 14 February 2012 BTG plc (LSE: BGC), the specialist healthcare company, announces that Rolf Soderstrom will no longer be leaving the company at the end of March and will continue in...
London, UK, 30 January 2012 Study meets all primary, secondary and tertiary endpoints BTG plc (LSE: BGC), the specialist healthcare company, today announces the successful outcome of VANISH-2, the...
London, UK, 25 January 2012 BTG plc (LSE: BGC), the specialist healthcare company, today publishes its interim management statement for the period from 1 October 2011 to 24 January 2012. Trading...
London, UK, 18 January 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces that it has received regulatory approval from the US Food and Drug Administration (FDA) for its...
London, UK, 11 January 2012 BTG plc (LSE: BGC), the specialist healthcare company today announces that it will be presenting at the 30th Annual J.P. Morgan Conference on Wednesday 11 January at...
London, UK, 11 December 2012 BTG plc (LSE: BTG), the specialist healthcare company, notes the announcement by Janssen that the US Food and Drug Administration (FDA) has approved the use of...